New launches going well for Almirall at the start of 2023

9 May 2023

Spanish dermatology company Almirall (ALM: MC) has recorded net sales of 230 million euros ($253 million) in the first quarter of 2023, a 6% increase, and net income of 7.7 million euros.

The performance was underpinned by strong sales growth of the firm’s dermatology portfolio in Europe, including for Ilumetri (tildrakizumab).

The novel anti-interleukin (IL)-23p19 biologic is approved for moderate-to-severe plaque psoriasis, and has grown to reach 38 million euros in sales, a 41% increase from the same period of 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK